Literature DB >> 18694960

CD40 induces antigen transporter and immunoproteasome gene expression in carcinomas via the coordinated action of NF-kappaB and of NF-kappaB-mediated de novo synthesis of IRF-1.

Aristides Moschonas1, Maria Kouraki, Pauline G Knox, Efstathia Thymiakou, Dimitris Kardassis, Aristides G Eliopoulos.   

Abstract

Cancer cells may evade immune surveillance as a result of defective antigen processing and presentation. In this study, we demonstrate that CD40 ligation overcomes this defect through the coordinated action of the transcription factors NF-kappaB and interferon regulatory factor 1 (IRF-1). We show that unlike interferon signaling, which triggers the STAT1-mediated transcriptional activation of IRF-1, the ligation of CD40 in carcinomas induces the rapid upregulation of IRF-1 in a STAT1-independent but NF-kappaB-dependent manner. The transcriptional activation of IRF-1 is controlled largely by the recruitment of p65 (RelA) NF-kappaB to the IRF-1 promoter following the engagement of a TAK1/IkappaB kinase beta/IkappaBalpha signaling pathway downstream of CD40. NF-kappaB and de novo-synthesized IRF-1 converge to regulate the expression of genes involved in antigen processing and transport, as evident from the sequential recruitment of NF-kappaB and IRF-1 to the promoters of the genes encoding transporter for antigen processing 1 (TAP1), TAP2, tapasin, and low-molecular-mass polypeptides LMP2 and LMP10. Moreover, the RNA interference-mediated knockdown of IRF-1 reduced, whereas the inhibition of NF-kappaB abolished, the effects of CD40 on TAP1 and LMP2 upregulation in carcinoma cells. Collectively, these data reveal a novel "feed-forward" mechanism induced by NF-kappaB which ensures that acutely synthesized IRF-1 operates in concert with NF-kappaB to amplify the immunoproteasome and antigen-processing functions of CD40.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18694960      PMCID: PMC2577429          DOI: 10.1128/MCB.00611-08

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  72 in total

Review 1.  The optimization of peptide cargo bound to MHC class I molecules by the peptide-loading complex.

Authors:  Tim Elliott; Anthony Williams
Journal:  Immunol Rev       Date:  2005-10       Impact factor: 12.988

Review 2.  The IRF family transcription factors in immunity and oncogenesis.

Authors:  Tomohiko Tamura; Hideyuki Yanai; David Savitsky; Tadatsugu Taniguchi
Journal:  Annu Rev Immunol       Date:  2008       Impact factor: 28.527

3.  SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase.

Authors:  B L Bennett; D T Sasaki; B W Murray; E C O'Leary; S T Sakata; W Xu; J C Leisten; A Motiwala; S Pierce; Y Satoh; S S Bhagwat; A M Manning; D W Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

4.  Restoration of the expression of transporters associated with antigen processing in lung carcinoma increases tumor-specific immune responses and survival.

Authors:  Yuanmei Lou; Timothy Z Vitalis; Genc Basha; Bing Cai; Susan S Chen; Kyung Bok Choi; Andrew P Jeffries; W Mark Elliott; Derek Atkins; Barbara Seliger; Wilfred A Jefferies
Journal:  Cancer Res       Date:  2005-09-01       Impact factor: 12.701

5.  Kinase MEKK1 is required for CD40-dependent activation of the kinases Jnk and p38, germinal center formation, B cell proliferation and antibody production.

Authors:  Ewen Gallagher; Thomas Enzler; Atsushi Matsuzawa; Amy Anzelon-Mills; Dennis Otero; Ryan Holzer; Edith Janssen; Min Gao; Michael Karin
Journal:  Nat Immunol       Date:  2006-12-03       Impact factor: 25.606

6.  Tumor suppression by IFN regulatory factor-1 is mediated by transcriptional down-regulation of cyclin D1.

Authors:  Andrea Kröger; Anja Stirnweiss; Julia Elisabeth Pulverer; Katjana Klages; Martina Grashoff; Jörg Reimann; Hansjörg Hauser
Journal:  Cancer Res       Date:  2007-04-01       Impact factor: 12.701

7.  Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.

Authors:  Robert H Vonderheide; Keith T Flaherty; Magi Khalil; Molly S Stumacher; David L Bajor; Natalie A Hutnick; Patricia Sullivan; J Joseph Mahany; Maryann Gallagher; Amy Kramer; Stephanie J Green; Peter J O'Dwyer; Kelli L Running; Richard D Huhn; Scott J Antonia
Journal:  J Clin Oncol       Date:  2007-03-01       Impact factor: 44.544

8.  TRAF6 is required for TRAF2-dependent CD40 signal transduction in nonhemopoietic cells.

Authors:  Clare C Davies; Tak W Mak; Lawrence S Young; Aristides G Eliopoulos
Journal:  Mol Cell Biol       Date:  2005-11       Impact factor: 4.272

9.  Recombinant CD40 ligand therapy has significant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin.

Authors:  S Ghamande; B L Hylander; E Oflazoglu; S Lele; W Fanslow; E A Repasky
Journal:  Cancer Res       Date:  2001-10-15       Impact factor: 12.701

10.  TNF activates an IRF1-dependent autocrine loop leading to sustained expression of chemokines and STAT1-dependent type I interferon-response genes.

Authors:  Anna Yarilina; Kyung-Hyun Park-Min; Taras Antoniv; Xiaoyu Hu; Lionel B Ivashkiv
Journal:  Nat Immunol       Date:  2008-03-16       Impact factor: 25.606

View more
  15 in total

1.  Identification of E2F1 as an important transcription factor for the regulation of tapasin expression.

Authors:  Juergen Bukur; Felix Herrmann; Diana Handke; Christian Recktenwald; Barbara Seliger
Journal:  J Biol Chem       Date:  2010-07-27       Impact factor: 5.157

2.  HMME-based PDT restores expression and function of transporter associated with antigen processing 1 (TAP1) and surface presentation of MHC class I antigen in human glioma.

Authors:  Shan-Yi Zhang; Jun-Liang Li; Xin-Ke Xu; Mei-Guang Zheng; Cheng-Cai Wen; Fang-Cheng Li
Journal:  J Neurooncol       Date:  2011-04-26       Impact factor: 4.130

3.  Cell adhesion tunes inflammatory TPL2 kinase signal transduction.

Authors:  Maria Vougioukalaki; Konstantina Georgila; Emmanouil I Athanasiadis; Aristides G Eliopoulos
Journal:  Cell Mol Life Sci       Date:  2022-02-26       Impact factor: 9.261

4.  Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer.

Authors:  Dawid Walerych; Kamil Lisek; Roberta Sommaggio; Silvano Piazza; Yari Ciani; Emiliano Dalla; Katarzyna Rajkowska; Katarzyna Gaweda-Walerych; Eleonora Ingallina; Claudia Tonelli; Marco J Morelli; Angela Amato; Vincenzo Eterno; Alberto Zambelli; Antonio Rosato; Bruno Amati; Jacek R Wiśniewski; Giannino Del Sal
Journal:  Nat Cell Biol       Date:  2016-06-27       Impact factor: 28.824

5.  The hydroxyflavone, fisetin, suppresses mast cell activation induced by interaction with activated T cell membranes.

Authors:  K Nagai; Y Takahashi; I Mikami; T Fukusima; H Oike; M Kobori
Journal:  Br J Pharmacol       Date:  2009-08-20       Impact factor: 8.739

6.  Viral IL-10 down-regulates the "MHC-I antigen processing operon" through the NF-κB signaling pathway in nasopharyngeal carcinoma cells.

Authors:  Yan-Xin Ren; Jie Yang; Rui-Mei Sun; Li-Juan Zhang; Liu-Fang Zhao; Bao-Zhong Li; Lei Li; Hai-Ting Long; Qiang-Ming Sun; Yun-Chao Huang; Xiao-Jiang Li
Journal:  Cytotechnology       Date:  2016-09-20       Impact factor: 2.058

7.  IRF-1 mediates the suppressive effects of mTOR inhibition on arterial endothelium.

Authors:  Kai Peng; Xing Fan; Qiannan Li; Yiying Wang; Xiaolin Chen; Pingxi Xiao; Anthony G Passerini; Scott I Simon; ChongXiu Sun
Journal:  J Mol Cell Cardiol       Date:  2020-02-19       Impact factor: 5.000

Review 8.  Trash Talk: Mammalian Proteasome Regulation at the Transcriptional Level.

Authors:  Hatem Elif Kamber Kaya; Senthil K Radhakrishnan
Journal:  Trends Genet       Date:  2020-09-25       Impact factor: 11.639

9.  IRF1 and NF-kB restore MHC class I-restricted tumor antigen processing and presentation to cytotoxic T cells in aggressive neuroblastoma.

Authors:  Silvia Lorenzi; Matteo Forloni; Loredana Cifaldi; Chiara Antonucci; Arianna Citti; Renata Boldrini; Marco Pezzullo; Aurora Castellano; Vincenzo Russo; Pierre van der Bruggen; Patrizio Giacomini; Franco Locatelli; Doriana Fruci
Journal:  PLoS One       Date:  2012-10-05       Impact factor: 3.240

10.  Removal of damaged proteins during ES cell fate specification requires the proteasome activator PA28.

Authors:  Malin Hernebring; Åsa Fredriksson; Maria Liljevald; Marija Cvijovic; Karin Norrman; John Wiseman; Henrik Semb; Thomas Nyström
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.